The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.

Alexandra FreyKatja Piras-StraubAndreas WalkerJörg TimmGuido GerkenKerstin Herzer

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2017)

For patients with HCV GT2a, GT3a, or GT4a infection, mTOR-based immunosuppressive therapy may be beneficial. CNI-based therapy may be more efficacious in GT1b patients, as mTOR inhibitors seem to impair antiviral efficacy of DAAs in HCV GT1b infection.

Keyphrases

hepatitis c virus
human immunodeficiency virus
end stage renal disease
cell proliferation
chronic kidney disease
newly diagnosed
stem cells
peritoneal dialysis
cell therapy
prognostic factors
bone marrow
patient reported outcomes
mesenchymal stem cells
hiv infected